BiologicalDrug
Fresolimumab clinical trials
Also written GC1008.
- studies test it
- 12
- open now
- 0
- in phase 3
- 0
- first study started
- 2005
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
12 studies that test it; most in 2011 (4)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 1 |
| 2016 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 8
Genzyme, a Sanofi Company (4) · Baylor College of Medicine (1) · University Medical Center Groningen (1) · Maximilian Diehn (1) · Abramson Cancer Center at Penn Medicine (1) · National Cancer Institute (NCI) (1) · Weill Medical College of Cornell University (1) · Boston University (1)
Studies
Open first, then newest update. How each study uses fresolimumab is read from its arms, and is right about nine times in ten.
Testing it · 12
- Safety of Fresolimumab in the Treatment of Osteogenesis ImperfectaCompletedPhase 1Baylor College of MedicineNCT03064074Written as Fresolimumab
- Safety and Imaging Study of GC1008 in GliomaCompletedPhase 2University Medical Center GroningenNCT01472731Written as GC1008
- SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung CancerCompletedPhase 1/2Maximilian DiehnNCT02581787Written as Fresolimumab
- Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural MesotheliomaCompletedPhase 2Abramson Cancer Center at Penn MedicineNCT01112293Written as GC1008
- Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma)CompletedPhase 1National Cancer Institute (NCI)NCT00923169Written as Anti-Transforming Growth Factor-beta (GC 1008)
- Fresolimumab and Radiotherapy in Metastatic Breast CancerCompletedPhase 2Weill Medical College of Cornell UniversityNCT01401062Written as Fresolimumab
- A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)CompletedPhase 2Genzyme, a Sanofi CompanyNCT01665391Written as fresolimumab
- Study of GC1008 in Patients With Idiopathic Pulmonary Fibrosis (IPF)CompletedPhase 1Genzyme, a Sanofi CompanyNCT00125385Written as GC1008
- Anti-TGF-beta Therapy in Patients With MyelofibrosisTerminatedPhase 1John MascarenhasNCT01291784Written as monoclonal antibody to TGF-beta
- Fresolimumab In Systemic SclerosisCompletedPhase 1Boston UniversityNCT01284322Written as Fresolimumab
- Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant MelanomaCompletedPhase 1Genzyme, a Sanofi CompanyNCT00356460Written as GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody
- Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGSCompletedPhase 1Genzyme, a Sanofi CompanyNCT00464321Written as GC1008
Codes
What other systems call fresolimumab · ClinicalTrials.gg INT005888
- MeSH (NLM) C560928fresolimumabOne source NLM
- UNII (FDA) 375142VBIAFRESOLIMUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q3753116fresolimumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C63546FresolimumabOne source FDA
- DrugBank DB12396One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C560928 | fresolimumab | One source NLM |
| UNII (FDA) | 375142VBIA | FRESOLIMUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q3753116 | fresolimumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C63546 | Fresolimumab | One source FDA |
| DrugBank | DB12396 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.